Want to see IKT full AI Analyst Report?
IKT Stock Chart & Stats
$1.83
$0.06(1.71%)
At close: 4:00 PM EST
$1.83
$0.06(1.71%)
Day’s Range― - ―
52-Week Range$1.33 - $2.26
Previous CloseN/A
Volume38.02K
Average Volume (3M)132.72K
Market Cap
$269.35M
Enterprise Value$172.24M
Total Cash (Recent Filing)$170.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 17, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding132,032,640
10 Day Avg. Volume124,469
30 Day Avg. Volume132,718
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.17
Price to Sales (P/S)0.00
P/FCF Ratio-7.25
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.19
Forecast
1Y Price Target
$6.00Price Target Upside227.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$500.00K
Bulls Say, Bears Say
Bulls Say
Low Debt And Substantial Equity BaseNear-zero debt and roughly $168M of equity provide material solvency and financing flexibility for a clinical-stage biotech. This durable balance-sheet strength reduces near-term refinancing risk and supports continued R&D and trial execution over the next 2–6 months.
Pivotal Phase 3 Trial InitiationAdvancing IKT-001 into a global, adaptive Phase 3 is a structural operational milestone that meaningfully derisks the program if successful. A pivotal trial creates a clear regulatory pathway and can convert the company from pre-revenue developer to potential commercial-stage firm over the medium term.
Governance Approval Bolsters Talent RetentionBoard and shareholder approval to expand the equity incentive pool and formalize governance protections strengthens the company's ability to retain and motivate management and key hires long-term, supporting consistent execution of clinical and regulatory programs.
Bears Say
No Product Revenue And Large Operating LossesSustained zero revenue and recurring large net losses reflect a company still solely in R&D mode. Without commercial product sales, the business remains dependent on external funding until regulatory approval and launch, making the operating model financially fragile over the medium term.
Persistent Negative Operating And Free Cash FlowOngoing cash burn near ~$35M annually necessitates periodic financing to sustain trials and operations. Persistent negative cash flow constrains strategic optionality and increases execution risk if capital markets tighten or trial timelines extend, pressuring liquidity over months.
Equity Dilution Risk From Expanded Incentive PoolExpanding the equity incentive plan, combined with historical reliance on equity financing, implies likely future share issuance to fund operations or compensate staff. That structural dilution risk can erode existing shareholders' ownership and may recur until the company achieves sustainable revenues.
Inhibikase Therapeutics News
IKT FAQ
What was Inhibikase Therapeutics’s price range in the past 12 months?
Inhibikase Therapeutics lowest stock price was $1.33 and its highest was $2.26 in the past 12 months.
What is Inhibikase Therapeutics’s market cap?
Inhibikase Therapeutics’s market cap is $269.35M.
When is Inhibikase Therapeutics’s upcoming earnings report date?
Inhibikase Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 37 days.
How were Inhibikase Therapeutics’s earnings last quarter?
Inhibikase Therapeutics released its earnings results on May 12, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.108 by $0.008.
Is Inhibikase Therapeutics overvalued?
According to Wall Street analysts Inhibikase Therapeutics’s price is currently Undervalued.
Does Inhibikase Therapeutics pay dividends?
Inhibikase Therapeutics does not currently pay dividends.
What is Inhibikase Therapeutics’s EPS estimate?
Inhibikase Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Inhibikase Therapeutics have?
Inhibikase Therapeutics has 132,032,640 shares outstanding.
What happened to Inhibikase Therapeutics’s price movement after its last earnings report?
Inhibikase Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.108. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics?
Currently, no hedge funds are holding shares in IKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inhibikase Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (227.87% Upside)
$6.00 (227.87% Upside)
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.19%
12-Months-Change
Fundamentals
Return on Equity
-41.31%
Trailing 12-Months
Asset Growth
83.85%
Trailing 12-Months
Company Description
Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
IKT Stock 12 Month Forecast
Average Price Target
$6.00
▲(227.87% Upside)
Technical Analysis
Atossa Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
TScan Therapeutics
―
Ownership Overview
12.28% Insiders
5.43% Mutual Funds
67.41% Other Institutional Investors
6.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---